Do analysts rate CVAC or TRDA?

Entrada Therapeutics has a consensus target price of $17.75, suggesting a potential upside of 162.96%. Given Entrada Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Entrada Therapeutics is more favorable than CureVac. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CureVac 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Entrada Therapeutics 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has stronger valuation & earnings, CVAC or TRDA?

CureVac has higher revenue and earnings than Entrada Therapeutics. Entrada Therapeutics is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CureVac $70.74M 14.78 $175.50M $0.72 6.47 Entrada Therapeutics $25.42M 10.34 -$143.75M -$3.96 N/A

Entrada Therapeutics (TRDA) Competitors

$6.75 -0.15 (-2.17%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$6.76 +0.01 (+0.15%)

As of 09/18/2026 04:21 PM Eastern

Compare

TRDA vs. SVRA, MLTX, JANX, CVAC, and KURA

Should you buy Entrada Therapeutics stock or one of its competitors? Entrada Therapeutics's main competitors and comparable companies include Savara (SVRA), MoonLake Immunotherapeutics (MLTX), Janux Therapeutics (JANX), CureVac (CVAC), and Kura Oncology (KURA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Entrada Therapeutics compare to Savara?

Savara (NASDAQ:SVRA) and Entrada Therapeutics (NASDAQ:TRDA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, media sentiment, earnings and dividends.

87.9% of Savara shares are held by institutional investors. Comparatively, 86.4% of Entrada Therapeutics shares are held by institutional investors. 5.3% of Savara shares are held by company insiders. Comparatively, 9.5% of Entrada Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Savara has a beta of 0.25, suggesting that its stock price is 75% less volatile than the broader market. Comparatively, Entrada Therapeutics has a beta of -0.25, suggesting that its stock price is 125% less volatile than the broader market.

Savara has a net margin of 0.00% compared to Entrada Therapeutics' net margin of -3,537.73%. Entrada Therapeutics' return on equity of -57.61% beat Savara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Savara	N/A	-90.28%	-68.95%
Entrada Therapeutics	-3,537.73%	-57.61%	-46.54%

Savara has higher earnings, but lower revenue than Entrada Therapeutics. Savara is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Savara	N/A	N/A	-$118.84M	-$0.58	N/A
Entrada Therapeutics	$25.42M	10.34	-$143.75M	-$3.96	N/A

Savara currently has a consensus price target of $10.00, suggesting a potential upside of 86.22%. Entrada Therapeutics has a consensus price target of $17.75, suggesting a potential upside of 162.96%. Given Entrada Therapeutics' higher possible upside, analysts clearly believe Entrada Therapeutics is more favorable than Savara.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Entrada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Savara had 1 more articles in the media than Entrada Therapeutics. MarketBeat recorded 1 mentions for Savara and 0 mentions for Entrada Therapeutics. Savara's average media sentiment score of 1.02 beat Entrada Therapeutics' score of 0.00 indicating that Savara is being referred to more favorably in the media.

Company	Overall Sentiment
Savara	Positive
Entrada Therapeutics	Neutral

Summary

Savara beats Entrada Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Entrada Therapeutics compare to MoonLake Immunotherapeutics?

MoonLake Immunotherapeutics (NASDAQ:MLTX) and Entrada Therapeutics (NASDAQ:TRDA) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, profitability, earnings, media sentiment, dividends, analyst recommendations and institutional ownership.

In the previous week, MoonLake Immunotherapeutics had 3 more articles in the media than Entrada Therapeutics. MarketBeat recorded 3 mentions for MoonLake Immunotherapeutics and 0 mentions for Entrada Therapeutics. MoonLake Immunotherapeutics' average media sentiment score of 0.27 beat Entrada Therapeutics' score of 0.00 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
MoonLake Immunotherapeutics	Neutral
Entrada Therapeutics	Neutral

Entrada Therapeutics has higher revenue and earnings than MoonLake Immunotherapeutics. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.84	N/A
Entrada Therapeutics	$25.42M	10.34	-$143.75M	-$3.96	N/A

93.9% of MoonLake Immunotherapeutics shares are owned by institutional investors. Comparatively, 86.4% of Entrada Therapeutics shares are owned by institutional investors. 10.4% of MoonLake Immunotherapeutics shares are owned by insiders. Comparatively, 9.5% of Entrada Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

MoonLake Immunotherapeutics has a beta of 1.04, indicating that its stock price is 4% more volatile than the broader market. Comparatively, Entrada Therapeutics has a beta of -0.25, indicating that its stock price is 125% less volatile than the broader market.

MoonLake Immunotherapeutics presently has a consensus price target of $24.57, indicating a potential upside of 98.32%. Entrada Therapeutics has a consensus price target of $17.75, indicating a potential upside of 162.96%. Given Entrada Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Entrada Therapeutics is more favorable than MoonLake Immunotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MoonLake Immunotherapeutics	3 Sell rating(s)	4 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.44
Entrada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

MoonLake Immunotherapeutics has a net margin of 0.00% compared to Entrada Therapeutics' net margin of -3,537.73%. Entrada Therapeutics' return on equity of -57.61% beat MoonLake Immunotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MoonLake Immunotherapeutics	N/A	-82.53%	-58.17%
Entrada Therapeutics	-3,537.73%	-57.61%	-46.54%

Summary

MoonLake Immunotherapeutics beats Entrada Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Entrada Therapeutics compare to Janux Therapeutics?

Entrada Therapeutics (NASDAQ:TRDA) and Janux Therapeutics (NASDAQ:JANX) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, institutional ownership, media sentiment, risk and dividends.

86.4% of Entrada Therapeutics shares are owned by institutional investors. Comparatively, 75.4% of Janux Therapeutics shares are owned by institutional investors. 9.5% of Entrada Therapeutics shares are owned by company insiders. Comparatively, 7.9% of Janux Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Janux Therapeutics had 8 more articles in the media than Entrada Therapeutics. MarketBeat recorded 8 mentions for Janux Therapeutics and 0 mentions for Entrada Therapeutics. Janux Therapeutics' average media sentiment score of 0.11 beat Entrada Therapeutics' score of 0.00 indicating that Janux Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Entrada Therapeutics	Neutral
Janux Therapeutics	Neutral

Entrada Therapeutics presently has a consensus target price of $17.75, indicating a potential upside of 162.96%. Janux Therapeutics has a consensus target price of $36.46, indicating a potential upside of 119.78%. Given Entrada Therapeutics' higher probable upside, analysts plainly believe Entrada Therapeutics is more favorable than Janux Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entrada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Janux Therapeutics	2 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.67

Janux Therapeutics has a net margin of 0.00% compared to Entrada Therapeutics' net margin of -3,537.73%. Janux Therapeutics' return on equity of -11.89% beat Entrada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entrada Therapeutics	-3,537.73%	-57.61%	-46.54%
Janux Therapeutics	N/A	-11.89%	-11.13%

Janux Therapeutics has lower revenue, but higher earnings than Entrada Therapeutics. Janux Therapeutics is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entrada Therapeutics	$25.42M	10.34	-$143.75M	-$3.96	N/A
Janux Therapeutics	$10M	101.43	-$113.62M	-$1.64	N/A

Entrada Therapeutics has a beta of -0.25, indicating that its stock price is 125% less volatile than the broader market. Comparatively, Janux Therapeutics has a beta of 2.53, indicating that its stock price is 153% more volatile than the broader market.

Summary

Janux Therapeutics beats Entrada Therapeutics on 12 of the 17 factors compared between the two stocks.

How does Entrada Therapeutics compare to CureVac?

CureVac (NASDAQ:CVAC) and Entrada Therapeutics (NASDAQ:TRDA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and institutional ownership.

Entrada Therapeutics has a consensus target price of $17.75, suggesting a potential upside of 162.96%. Given Entrada Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Entrada Therapeutics is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CureVac	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Entrada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

CureVac has a beta of 1.77, meaning that its share price is 77% more volatile than the broader market. Comparatively, Entrada Therapeutics has a beta of -0.25, meaning that its share price is 125% less volatile than the broader market.

CureVac has a net margin of 199.92% compared to Entrada Therapeutics' net margin of -3,537.73%. CureVac's return on equity of -23.03% beat Entrada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CureVac	199.92%	-23.03%	-19.09%
Entrada Therapeutics	-3,537.73%	-57.61%	-46.54%

17.3% of CureVac shares are held by institutional investors. Comparatively, 86.4% of Entrada Therapeutics shares are held by institutional investors. 2.2% of CureVac shares are held by insiders. Comparatively, 9.5% of Entrada Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

CureVac has higher revenue and earnings than Entrada Therapeutics. Entrada Therapeutics is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47
Entrada Therapeutics	$25.42M	10.34	-$143.75M	-$3.96	N/A

In the previous week, CureVac's average media sentiment score of 0.00 equaled Entrada Therapeutics'average media sentiment score.

Company	Overall Sentiment
CureVac	Neutral
Entrada Therapeutics	Neutral

Summary

CureVac beats Entrada Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Entrada Therapeutics compare to Kura Oncology?

Kura Oncology (NASDAQ:KURA) and Entrada Therapeutics (NASDAQ:TRDA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, institutional ownership, profitability, media sentiment, risk and dividends.

Kura Oncology presently has a consensus price target of $25.40, indicating a potential upside of 116.54%. Entrada Therapeutics has a consensus price target of $17.75, indicating a potential upside of 162.96%. Given Entrada Therapeutics' higher probable upside, analysts clearly believe Entrada Therapeutics is more favorable than Kura Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kura Oncology	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Entrada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Kura Oncology has a beta of 0.44, indicating that its share price is 56% less volatile than the broader market. Comparatively, Entrada Therapeutics has a beta of -0.25, indicating that its share price is 125% less volatile than the broader market.

Kura Oncology has a net margin of -384.30% compared to Entrada Therapeutics' net margin of -3,537.73%. Entrada Therapeutics' return on equity of -57.61% beat Kura Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kura Oncology	-384.30%	-207.18%	-45.17%
Entrada Therapeutics	-3,537.73%	-57.61%	-46.54%

86.4% of Entrada Therapeutics shares are held by institutional investors. 7.6% of Kura Oncology shares are held by company insiders. Comparatively, 9.5% of Entrada Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Kura Oncology had 3 more articles in the media than Entrada Therapeutics. MarketBeat recorded 3 mentions for Kura Oncology and 0 mentions for Entrada Therapeutics. Kura Oncology's average media sentiment score of 0.34 beat Entrada Therapeutics' score of 0.00 indicating that Kura Oncology is being referred to more favorably in the media.

Company	Overall Sentiment
Kura Oncology	Neutral
Entrada Therapeutics	Neutral

Entrada Therapeutics has lower revenue, but higher earnings than Kura Oncology. Kura Oncology is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kura Oncology	$67.48M	15.46	-$278.67M	-$3.37	N/A
Entrada Therapeutics	$25.42M	10.34	-$143.75M	-$3.96	N/A

Summary

Kura Oncology beats Entrada Therapeutics on 10 of the 16 factors compared between the two stocks.

Get Entrada Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TRDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TRDA vs. The Competition

Export

Metric	Entrada Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$268.66M	$3.92B	$7.25B	$13.14B
Dividend Yield	N/A	3.65%	2.57%	12.30%
P/E Ratio	-1.70	14.30	275.79	25.40
Price / Sales	10.34	1,415.50	695.58	114.44
Price / Cash	N/A	110.75	77.42	51.66
Price / Book	0.84	15.45	10.46	6.33
Net Income	-$143.75M	-$22.86M	$3.49B	$358.33M
7 Day Performance	-0.74%	-1.21%	0.59%	1.12%
1 Month Performance	-13.24%	-4.42%	-2.01%	-2.67%
1 Year Performance	24.54%	37.81%	18.09%	6.01%

Entrada Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TRDA Entrada Therapeutics	2.254 of 5 stars	$6.75 -2.2%	$17.75 +163.0%	+21.6%	$268.66M	$25.42M	N/A	152	Analyst Downgrade
SVRA Savara	2.0644 of 5 stars	$5.26 -1.5%	$10.00 +90.1%	+49.2%	$1.10B	N/A	N/A	70	Positive News
MLTX MoonLake Immunotherapeutics	2.0868 of 5 stars	$12.20 -3.8%	$24.57 +101.4%	-77.1%	$1.08B	N/A	N/A	130	News Coverage Analyst Forecast
JANX Janux Therapeutics	3.0504 of 5 stars	$16.44 -5.0%	$36.46 +121.8%	-32.0%	$1.06B	$10M	N/A	113
CVAC CureVac	N/A	$4.66 flat	N/A	N/A	$1.05B	$70.74M	6.47	880

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TRDA) was last updated on 9/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Entrada Therapeutics (TRDA) Competitors

TRDA vs. SVRA, MLTX, JANX, CVAC, and KURA

How does Entrada Therapeutics compare to Savara?

Summary

How does Entrada Therapeutics compare to MoonLake Immunotherapeutics?

Summary

How does Entrada Therapeutics compare to Janux Therapeutics?

Summary

How does Entrada Therapeutics compare to CureVac?

Summary

How does Entrada Therapeutics compare to Kura Oncology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRDA vs. The Competition

Entrada Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Entrada Therapeutics (TRDA) Competitors

TRDA vs. SVRA, MLTX, JANX, CVAC, and KURA

How does Entrada Therapeutics compare to Savara?

Do insiders & institutionals hold more shares of SVRA or TRDA?

Which has more volatility & risk, SVRA or TRDA?

Is SVRA or TRDA more profitable?

Which has stronger earnings and valuation, SVRA or TRDA?

Do analysts prefer SVRA or TRDA?

Does the media favor SVRA or TRDA?

Summary

How does Entrada Therapeutics compare to MoonLake Immunotherapeutics?

Does the media prefer MLTX or TRDA?

Which has higher valuation & earnings, MLTX or TRDA?

Do institutionals and insiders have more ownership in MLTX or TRDA?

Which has more risk and volatility, MLTX or TRDA?

Do analysts prefer MLTX or TRDA?

Is MLTX or TRDA more profitable?

Summary

How does Entrada Therapeutics compare to Janux Therapeutics?

Do institutionals and insiders believe in TRDA or JANX?

Does the media favor TRDA or JANX?

Do analysts recommend TRDA or JANX?

Is TRDA or JANX more profitable?

Which has better valuation & earnings, TRDA or JANX?

Which has more risk & volatility, TRDA or JANX?

Summary

How does Entrada Therapeutics compare to CureVac?

Do analysts rate CVAC or TRDA?

Which has more risk & volatility, CVAC or TRDA?

Is CVAC or TRDA more profitable?

Do institutionals and insiders hold more shares of CVAC or TRDA?

Which has stronger valuation & earnings, CVAC or TRDA?

Does the media refer more to CVAC or TRDA?

Summary

How does Entrada Therapeutics compare to Kura Oncology?

Do analysts recommend KURA or TRDA?

Which has more volatility and risk, KURA or TRDA?

Is KURA or TRDA more profitable?

Do institutionals & insiders believe in KURA or TRDA?

Does the media refer more to KURA or TRDA?

Which has preferable valuation & earnings, KURA or TRDA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRDA vs. The Competition

Entrada Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools